Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma

Neoplasma

Volumn 53, Issue 2, 2006, Pages 174-181

  Elbl, L ^a   Vasova, I ^a   Tomaskova, I ^a   Jedlicka, F ^a   Navratil, M ^a   Pospisil, Z ^b   Vorlicek, J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Cardiotoxicity; Doxorubicin; Non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CARDIOPULMONARY FUNCTION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DOPPLER FLOWMETRY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART PERFORMANCE; HUMAN; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; RISK FACTOR;

EID: 33645471849     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. MESSORI A, VAIANI M, TRIPPOLI S. Survival in patients with intermediate or high-grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001; 84: 303-307.
2. VONHOFF DD, LAYARD MW, BASA P, DAVIS HL, VONHOFF AL et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
3. SCHWARTZ R, MCKENZIE W, ALEXANDER J, SAGER P, D'SOUZA A et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1109-1118.
4. SHAN K, LINCOFF M, YOUNG J. Anthracycline-induced cardiotoxicity. Am Intern Med 1996; 125: 47-58.
5. KRISHER JP, EPSTEIN S, GUTHBERTSON DD, GOORIN AM, EPSTEIN ML et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997; 15: 1544-1552.
6. LIPSHULTZ SE, COLAN SD, GELBER RD, PERES-ATAYDE AR, SALLAN SE et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Eng J Med 1991; 324: 808-815.
7. STEINHERZ LJ, STEINHERZ PG, TAN CHTC, HELLER G, MURPHY ML. Cardiac toxicity 4 to 20 years after completing anhtracycline therapy. JAMA 1991; 266: 1672-1677.
8. OTTO CM. Echocardiographic evaluation of left and right ventricular systolic function. In: Otto CM. Textbook of Clinical Echocardiography. Second edition. Philadelphia: WB Saunders Comp, 2000: 100-131.
9. TEI CH, LIENG H, HODGE DO, BAILEY KR, OH JK et al. New index of combined systolic and diastolic myocardial performance: A simple and reproducible measure of cardiac function. A study in normals and dilated cardiomyopathy. J Cardiol 1995; 26: 357-366.
10. BECK KC, WEISMAN IM. Methods for cardiopulmonary exercise testing. In: Weisman IM, Zeballos RJ. Clinical Exercise Testing. Prog Respir Res Basel: Karger, 2002; 32: 43-59.
11. GHARIB MI, BURNETT AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2004; 4: 235-242.
12. GIANTRIS A, ABDURRAHMAN L, HINKLE A, ASSELIN B, LIPSHULTZ SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rew Oncol Hematol 1998; 27: 53-68.
13. FOON KA, SAFA MM. Biologic therapy of lymphoma. In: Mauch PM, Armitage JO, Coiffer B, Dalla-Favera R, Harris NL, editors. Non-Hodgkin's Lymphoma. Philadelphia: Lippincot William&Wilkins, 2004: 221-235.
14. AYASH LJ, WRIGHT JE, TRETYAKOV O, GONIN R, ELIAS A et al. Cyclophosphamide phramacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000.
15. BRAVERMAN AC, ANTIN JH, PLAPPERT MT, COOK EF, LEE RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-1223.
16. BOIVIN JF, HUTCHISON GB, LUBIN JH, MAUCH P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992; 69: 1241-1247.
17. HANCOCK SL, TUCKER MA, HOPPE RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949-1955.
18. BOUCEK RJ, DODD DA, ATKINSON JB, OQUIST N, OLSON RD. Contractile failure in chronic doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol 1997; 29: 2631-2641.
19. DILLON TA, SULLIVAN M, SCHATZLEIN MH, PETERSON AC, SCHEERINGA RH et al. Cardiac transplantation in patients with preexisting malignancies. Transplantation 1991; 52: 82-85.
20. GRENIER MA, LIPSHULTZ SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25: 72-85.
21. SINGAL P, ILISKOVIC N. Current concepts: doxorubicin-induced cardiotoxicity. N Engl J Med 1998; 339: 900-905.
22. MILLER TP, DAHLBERG S, CASSADY JR, ADELSTEIN DJ, SPIER CM et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21-26.
23. HADDY TB, ADDE MA, MCCALLA J, DOMANSKI Y, DATILES M et al. Late effects in long-term survivors of high-grade non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 2070-2079.
24. LIMAT S, DEMESMAY K, VOILLAT L, BERNARD Y, DECONINCK E et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14: 277-281.
25. NYSOM K, COLAN CD, LIPSHULTZ SE. Late cardiotoxicity following anthracycline therapy for childhood cancer. Progr Ped Cardiol 1998; 8: 121-138.
26. ALEXANDER J, DAINIAK N, BERGER H, GOLDMAN L, JOHNASTONE D et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979; 300: 278-283.
27. GANZ WI, SRIDHAR KS, GANZ SS, GONZALES R, CHAKKO S et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53: 461-470.
28. STEINHERZ LJ, GRAHAM T, HURWITZ R. Guidelines for Cardiac Monitoring of Children During and After Anthracycline Therapy: Report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89: 942-948.
29. ELBL L, HRSTKOVA H, CHALOUPKA V. Dynamic stress echocardiography in asymptomatic patients treated for a malignant disease in childhood. Pol Heart J 2003; 58: 190-196.
30. COHN JN, JOHNSON G. Heart failure with normal ejection fraction. The V-HeFT Study. Circulation 1990; 81: 48-53.
31. LITWIN SE, GROSSMAN W. Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol 1993; 22: 49-55.
32. ATHERTON JJ, MOORE TD, THOMSON HL, FRENNEAUX MP. Restrictive left ventricular filling patterns are predictive of diastolic ventricular interaction in chronic heart failure. J Am Coll Cardiol 1998; 31: 413-418.
33. GIANNUZZI P, TEMPORELLI PL, BOSIMINI E, SILVA P, IMPARATO A et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol 1996; 28: 383-390.
34. XIE GY, BERK MR, SMITH MD, GURLEY JC, DEMARIA AN. Prognostic value of Doppler transmitral flow patterns in patients with congestive heart failure. J Am Coll Cardiol 1994; 24: 132-139.
35. BOTTONE AE, DEBEER EL, VOEST EE. Anthracyclines enhance tension development in cardiac muscle by direct interaction with the contractile system. J Mol Cell Cardiol 1997; 29: 1001-1008.
36. KANG YJ. Molecular and cellular mechanisms of cardiotoxicity. Environ Health Perspect 2001; 109: 27-34.
37. TEI CH, NISHIMURA RA, SEWARD JB, TAJIK AJ. Noninvasive Doppler-derived myocardial performance index: Correlation with simultaneous measurements of cardiac catheterization measurements. J Am Soc Echocardiogr 1997; 10: 169-178.
38. BRUCH C, SCHMERMUND A, MARIN D, KATZ M, BARTEL T et al. Tei-index in patients with mild-to-moderate congestive heart failure. Eur Heart J 2000; 21: 1888-1895.
39. EIDEM BW, SAPP BG, SUAREZ CR, CETTA F. Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 2001; 87: 1120-1122.
40. OCKAL B, OGUZ D, KARADEMIR S, BIRGEN D, YUKSEK N et al. Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo/Doppler indices. Pediatr Cardiol 2002; 23: 522-527.
41. DUJARDIN KS, TEI CH, YEO TCH, HODGE DO, ROSSI A et al. Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol 1998; 82: 1071-1076.
42. HARJAI KJ, SCOTT L, VIVEKANANTHAN K, NUNEZ E, EDUPUGANTI R. The Tei index: A new prognostic index for patients with symptomatic heart failure. J Am Soc Echocardiogr 2002; 15: 864-868.
43. HOGARTY AN, SILBER JH, PARIDON SM. Cardiopulmonary exercise in evaluation of the functional capacity of survivors of childhood cancer. Progress Pediatr Cardiol 1998; 8: 109-119.
44. BELARDINELLI R, GEORGIOU D, PALOMBO C, ROSSI G, GHIONE S. Echo Doppler diastolic function and exercise tolerance. Circulation 1995; 91: 2775-2784.
45. EBERT AG, MARABOTTI C, PALOMBO C, GIACONI S, ROSSI G et al. Echo Doppler diastolic function and exercise tolerance. Int J Cardiol 1994; 43: 67-73.
46. SATO T, HARADA K, TAMURA M, WATANABE A, ISHII M et al. Cardiorespiratory exercise capacity and its relation to a new Doppler index in children previously treated with anthracycline. J Am Soc Echocardiogr 2001; 14: 256-263.
47. LIBONATI JR, CICCOLO J, GLASSBERG H. The Tei index and exercise capacity. J Sports Med Phys Fitness 2001; 41: 108-113.
48. NOUSIAINEN T, JANTUNEN E, VANNINEN E, REMES J, VUOLTEENAHO O et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Hematol 1999; 62: 135-141.
49. NOUSIAINEN T, VANNIKEN E, JANTUNEN E, REMES J, RITANEN E et al. Neuroendocrine changes during the evaluation of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. Clinical Science 2001; 101: 601-607.